StockNews.AI
CELU
StockNews.AI
2 days

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

1. Celularity filed its 10-Q reports for Q1 and Q2 2025. 2. Company regained Nasdaq compliance, enhancing investor confidence. 3. Retired $32 million debt, improving financial stability. 4. Plans to grow wound care sales and advance pipeline products. 5. CEO highlights focus on regenerative medicine and unmet therapeutic needs.

8m saved
Insight
Article

FAQ

Why Bullish?

Regaining Nasdaq compliance and debt retirement are strong positive indicators for CELU's stock performance. Historically, compliance with listing standards has resulted in stock price recoveries in similar cases.

How important is it?

The article outlines significant achievements that can boost investor confidence and sales potential. The importance lies in the company's operational improvements and positive financial restructuring.

Why Short Term?

The immediate filing of compliance reports and debt retirement suggest quick improvements in market perception and potential sales growth. Similar instances in the biotech sector have shown rapid investor response post-compliance.

Related Companies

Celeniv Pte. Ltd.
Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1). FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The Quarterly Reports on Form 10-Q can be accessed on the SEC's website at www.sec.gov and in the investor relations section of the Company’s website at https://celularity.com/sec-filings. “I am pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025, as a result of which we have regained compliance with the Nasdaq Listing Rule 5250(c)(1). This is another important step for Celularity, as it comes on the heels of the recently announced retirement of all $32.0 million of the Company’s senior secured debt plus $9.6 million in associated unpaid interest, the Asset Purchase Agreement and a License Agreement with Celeniv Pte. Ltd., and an internal restructuring that includes establishing operating subsidiaries for each of its functional business units,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and CEO. “The Company dealt with a set of challenges during the first half of 2025, including a significant secured debt overhang. As announced previously, we retired all senior secured debt and the associated general security interest on Company assets is now gone. Also in the first half of 2025, some since-resolved directional uncertainty around wound care product reimbursement policy added to the normal lag between commercial advanced biomaterial product sales and cash collections. Coming as it did on the heels of substantial growth in the second half of 2024 of our wound care related commercial product sales and Accounts Receivable, this factor contributed to working capital pressures during the first half of 2025. Today, however, we believe the Company is well positioned to access traditional working capital facilities, which we intend to use to fuel renewed wound care related sales growth and advance our three late stage 510(k) pipeline products, along with capitalizing on new opportunities like stem cell product sales in Florida and elsewhere,” Dr. Hariri added. About Celularity Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies that target fundamental aging mechanisms like cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com. Forward Looking Statements Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Related News